Clinical Trial Update: Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance

View source ↗

Summary

This clinical trial is investigating circulating tumor mitochondrial DNA as a biomarker to monitor recurrence in patients with hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Tongji Hospital | Conditions: Hepatocellular Carcinoma (HCC) | Status: RECRUITING